Desogestrel / Ethinylestradiol Tablets 0.15mg/0.03mg (Marvelon 21® / マーベロン21)

JPY ¥25,000

Japanese oral contraceptive (Desogestrel 0.15mg / Ethinylestradiol 0.03mg). Taken orally once daily for 21 days for contraception. 21 tablets (PTP) x 10. Mfd. by Organon K.K., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥23,000
10 - 19 12% JPY ¥22,000
20 + 18% JPY ¥20,500
SKU: MRV-015-TAB Category:

Description

Product Overview / 商品概要

Marvelon 21 Tablets (Desogestrel 0.15mg / Ethinylestradiol 0.03mg) (マーベロン21)
Generic: Desogestrel / Ethinylestradiol / デソゲストレル・エチニルエストラジオール
Therapeutic Category: Oral Contraceptive / 経口避妊剤
Manufactured by: Organon K.K. / オルガノン株式会社

Composition & Specification / 組成・規格

Active Ingredient: Desogestrel 0.15mg, Ethinylestradiol 0.03mg per tablet / デソゲストレル 0.15mg、日局 エチニルエストラジオール 0.03mg(1錠中)
Additives: Potato starch, Povidone, Stearic acid, Light anhydrous silicic acid, Tocopherol, Lactose hydrate, Hypromellose, Macrogol 400, Titanium dioxide, Talc / バレイショデンプン、ポビドン、ステアリン酸、軽質無水ケイ酸、トコフェロール、乳糖水和物、ヒプロメロース、マクロゴール400、酸化チタン、タルク
Appearance: White film-coated tablets, Identification code: TR5 ☆ORGANON, Weight: 66mg, Diameter: 5.0mm, Thickness: 2.9mm
外観: 白色のフィルムコーティング錠、識別コード: TR5 ☆ORGANON、重量66mg、直径5.0mm、厚さ2.9mm

Indications / 効能効果

EN: Contraception
JA: 避妊

Dosage and Administration / 用法用量

EN: Take 1 tablet orally once daily at the same time each day for 21 consecutive days, followed by a 7-day tablet-free interval. Repeat the same regimen for the duration of contraception.
JA: 1日1錠を毎日一定の時刻に計21日間連続経口投与し、その後7日間休薬する。同様の方法で、避妊する期間繰り返し投与する。

Contraindications / 禁忌

EN: Women with hypersensitivity to any component; patients with or suspected of estrogen-dependent malignancies (e.g., breast cancer, endometrial cancer), cervical cancer; patients with undiagnosed abnormal genital bleeding; patients with or history of thrombophlebitis, pulmonary embolism, cerebrovascular disorders, or coronary artery disease; women aged 35 or older who smoke 15 or more cigarettes per day; patients with migraine with aura; patients with valvular heart disease complicated by pulmonary hypertension or atrial fibrillation, or with history of subacute bacterial endocarditis; diabetic patients with vascular lesions; women with thrombophilic conditions; patients with antiphospholipid antibody syndrome; patients within 4 weeks before surgery, within 2 weeks after surgery, within 4 weeks postpartum, or in prolonged immobilization; patients with severe hepatic impairment; patients with hepatic tumors; patients with lipid metabolism disorders; patients with hypertension (except mild); patients with otosclerosis; patients with history of jaundice, persistent pruritus, or herpes gestationis during pregnancy; pregnant women or women who may be pregnant; breastfeeding women; women whose bone growth may not be complete
JA: 本剤の成分に対し過敏性素因のある女性、エストロゲン依存性悪性腫瘍(乳癌、子宮内膜癌等)・子宮頸癌及びその疑いのある患者、診断の確定していない異常性器出血のある患者、血栓性静脈炎・肺塞栓症・脳血管障害・冠動脈疾患またはその既往歴のある患者、35歳以上で1日15本以上の喫煙者、前兆を伴う片頭痛の患者、肺高血圧症または心房細動を合併する心臓弁膜症の患者・亜急性細菌性心内膜炎の既往歴のある心臓弁膜症の患者、血管病変を伴う糖尿病患者、血栓性素因のある女性、抗リン脂質抗体症候群の患者、手術前4週以内・術後2週以内・産後4週以内・長期間安静状態の患者、重篤な肝障害のある患者、肝腫瘍のある患者、脂質代謝異常のある患者、高血圧のある患者(軽度を除く)、耳硬化症の患者、妊娠中に黄疸・持続性そう痒症または妊娠ヘルペスの既往歴のある患者、妊婦または妊娠している可能性のある女性、授乳婦、骨成長が終了していない可能性がある女性

Regulatory Information / 規制情報

Approval No.: 21100AMY00154000
Sales Started: April 2005 / 2005年4月
Classification Code: 872549
Storage: Store at room temperature / 室温保存
Shelf Life: 3 years / 3年

Packaging / 包装

Main Package (for sale): 21 tablets (PTP) x 10 / 21錠(PTP)×10
Other Available Packages (by special order): 210 tablets [21 tablets (PTP) x 10], 1,050 tablets [21 tablets (PTP) x 50]

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Desogestrel / Ethinylestradiol Tablets 0.15mg/0.03mg (Marvelon 21® / マーベロン21)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Desogestrel

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.